Troglitazone → Epilepsy

Original Indication

Antidiabetic (withdrawn due to liver toxicity)

Proposed New Indication

Repurposing Troglitazone to target ferroptosis in epilepsy, leveraging its anti-inflammatory and oxidative stress modulating properties to protect against neuronal damage.

Proposed Mechanism

Targets: Ferroptosis, Neuroinflammation_Pathways, Mitochondrial_Dysfunction_Pathways

Troglitazone, a PPAR-gamma agonist, can modulate pathways involved in ferroptosis, reducing lipid peroxidation, neuroinflammation, and mitigating mitochondrial dysfunction, thereby offering neuroprotection in epilepsy.

Evidence

Level: Review (preclinical evidence and suggested repurposing)

Source: Shen D et al. The role of ferroptosis in epilepsy: mechanisms and targeted therapies. Biochem Pharmacol. 2026 Mar 20;249:117912.

Reference: PubMed 41865900

Repurposing Score